Searched for
MANKIND PHARMA BLOCK DEAL
Fidelity Investments buys 2 pc stake in Lodha Developers for Rs 1,864 croreFidelity Investments has strategically acquired a 2% stake in Lodha Developers, amounting to Rs 1,864 crore, through open market operations...- Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
- Vedanta may have a couple more tranches of promoter-driven selling; stock likely to bounce back in 1-2 weeks: Ambareesh BaligaVedanta shares saw a significant drop following a large block deal, but analysts suggest the selloff is temporary. Promoter entity Twin Sta...
- Stocks in news: Vedanta, Honasa Consumer, IRCTC, Bajaj Auto, Tata MotorsIndian markets experienced profit booking, falling over a percent amidst a weak global trend. Key stocks like Vedanta, Honasa Consumer, IRC...
- Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Promoter Twin Star sells Vedanta shares worth Rs 1,896 crore in block dealTwin Star Holdings, a promoter entity of Vedanta, sold 6.51 crore shares worth nearly Rs 1,896 crore through a block deal on Tuesday. The t...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
- Russia's premier geopolitical platform launched in Moscow with focus on regional conflictsMoscow is hosting the 12th 'Primakov Readings' forum, coinciding with IMEMO's 70th anniversary. Over 400 global experts are debating a "Wor...
- Vedanta Power, Oil & Gas, and Iron shares rally up to 5%; Aluminium sheds 3%. Should you buy, sell or hold?Vedanta’s newly demerged entities extended their rally, with Oil & Gas, Power and Iron & Steel hitting upper circuits, while Aluminium slip...
- Block deal alert! Craftsman Auto shares in focus as promoter to sell stake worth Rs 486 croreCraftsman Automation shares are under scrutiny as promoter Srinivasan Ravi plans to sell up to 2.01% stake via a block deal worth Rs 486 cr...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Societe General, Prudential, others buy 3 per cent stake in Anthem Biosciences for Rs 1,275 crGlobal investors including Societe Generale and Prudential Hong Kong, alongside Indian mutual funds and insurance companies, have bought a ...
- Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soonIndian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...
- US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisitionThe U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...
- Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, VedantaIndian markets experienced a volatile session, closing higher amidst mixed signals. Bulls are defending the 23,000 level in Nifty, but unce...
- Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
Load More
